Rivaroxaban Patent Expiration

Rivaroxaban is Used for reducing the risk of clot-related complications in various cardiovascular conditions, including deep vein thrombosis and pulmonary embolism in pediatric and adult patients. It was first introduced by Janssen Pharmaceuticals Inc in its drug Xarelto on Jul 1, 2011.


Rivaroxaban Patents

Given below is the list of patents protecting Rivaroxaban, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Xarelto US10828310 Reducing the risk of cardiovascular events Jan 31, 2039 Janssen Pharms
Xarelto US10828310

(Pediatric)

Reducing the risk of cardiovascular events Jul 31, 2039 Janssen Pharms
Xarelto US7157456 Substituted oxazolidinones and their use in the field of blood coagulation Aug 28, 2024 Janssen Pharms
Xarelto US7157456

(Pediatric)

Substituted oxazolidinones and their use in the field of blood coagulation Feb 28, 2025 Janssen Pharms
Xarelto US7585860 Substituted oxazolidinones and their use in the field of blood coagulation Dec 11, 2020

(Expired)

Janssen Pharms
Xarelto US7585860 Substituted oxazolidinones and their use in the field of blood coagulation Dec 11, 2020

(Expired)

Janssen Pharms
Xarelto US7592339 Substituted oxazolidinones and their use in the field of blood coagulation Dec 11, 2020

(Expired)

Janssen Pharms
Xarelto US9415053 Solid, orally administrable pharmaceutical composition Nov 13, 2024 Janssen Pharms
Xarelto US9415053

(Pediatric)

Solid, orally administrable pharmaceutical composition May 13, 2025 Janssen Pharms
Xarelto US9539218 Prevention and treatment of thromboembolic disorders Feb 17, 2034 Janssen Pharms
Xarelto US9539218

(Pediatric)

Prevention and treatment of thromboembolic disorders Aug 17, 2034 Janssen Pharms


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Rivaroxaban's patents.

Given below is the list recent legal activities going on the following patents of Rivaroxaban.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 26 Jun, 2024 US9539218
Payment of Maintenance Fee, 4th Year, Large Entity 24 Apr, 2024 US10828310
Payment of Maintenance Fee, 8th Year, Large Entity 31 Jan, 2024 US9415053
Termination or Final Written Decision 28 Jul, 2023 US10828310
Request for Trial Granted 19 Oct, 2022 US10828310
Petition Requesting Trial 30 Sep, 2022 US10828310
Petition Requesting Trial 27 Sep, 2022 US10828310
Petition Requesting Trial 09 Sep, 2022 US10828310
Petition Requesting Trial 08 Sep, 2022 US10828310
Request for Trial Granted 09 Aug, 2022 US10828310



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳